Home » Stocks » NBSE

NeuBase Therapeutics, Inc. (NBSE)

Stock Price: $3.75 USD -0.01 (-0.27%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 123.02M
Revenue (ttm) n/a
Net Income (ttm) -18.09M
Shares Out 23.18M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $3.75
Previous Close $3.76
Change ($) -0.01
Change (%) -0.27%
Day's Open 3.76
Day's Range 3.68 - 3.81
Day's Volume 106,717
52-Week Range 3.66 - 12.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PITTSBURGH, June 08, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of pre...

1 month ago - GlobeNewsWire

Expansion of management team continues with addition of an industry leader with deep experience in business development, licensing, and strategy in the life-science industry Expansion of management team...

2 months ago - GlobeNewsWire

Expansion of management team to support the Company's advancement of its first drug candidate into clinical trials next year and growth of therapeutic pipeline Expansion of management team to support th...

2 months ago - GlobeNewsWire

RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat  at 11:30 a.m. ET on May 19

2 months ago - GlobeNewsWire

PITTSBURGH, May 13, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of prec...

2 months ago - GlobeNewsWire

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

2 months ago - GlobeNewsWire

PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic m...

3 months ago - GlobeNewsWire

PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

3 months ago - GlobeNewsWire

PITTSBURGH, April 21, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic me...

3 months ago - GlobeNewsWire

One of its investors praised the company in a quarterly performance update.

6 months ago - The Motley Fool

David Einhorn (Trades, Portfolio)'s hedge fund, Greenlight Capital, ended 2020 on a high note. After a rough start to the year, Greenlight added 25% in the fourth quarter of 2020, making it the best qua...

Other stocks mentioned: GRBK, HON, REZI
6 months ago - GuruFocus

PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of syn...

6 months ago - GlobeNewsWire

Data presented throughout 2020 have validated the potential of the PATrOL™ platform to develop highly targeted therapies that increase, decrease or change causal protein function

7 months ago - GlobeNewsWire

Registration For This FREE Tribe Public Presentation and Q&A Event Is Now Open at NeuBase22.TribePublic.com SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2020 / Tribe Public announced today that Dietric...

7 months ago - Accesswire

PITTSBURGH, Nov. 23, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of syn...

8 months ago - GlobeNewsWire

PITTSBURGH, Nov. 10, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of syn...

8 months ago - GlobeNewsWire

PITTSBURGH, Sept. 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of ...

9 months ago - GlobeNewsWire

PITTSBURGH, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of ...

10 months ago - GlobeNewsWire

Strong Pharmacokinetic and Pharmacodynamic Data Presented in March Validate Platform and Position Company for Scalable Output of Synthetic Precision Genetic Medicines

11 months ago - GlobeNewsWire

NeuBase (NBSE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

About NBSE

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. Ne... [Read more...]

Industry
Biotechnology
CEO
Dietrich Stephan
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
NBSE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for NBSE stock is "Strong Buy." The 12-month stock price forecast is 16.50, which is an increase of 340.00% from the latest price.

Price Target
$16.50
(340.00% upside)
Analyst Consensus: Strong Buy